ATRA vs. ATHA, CVM, PLX, ALVR, PASG, GRTS, CGTX, DTIL, CRIS, and ELUT
Should you be buying Atara Biotherapeutics stock or one of its competitors? The main competitors of Atara Biotherapeutics include Athira Pharma (ATHA), CEL-SCI (CVM), Protalix BioTherapeutics (PLX), AlloVir (ALVR), Passage Bio (PASG), Gritstone bio (GRTS), Cognition Therapeutics (CGTX), Precision BioSciences (DTIL), Curis (CRIS), and Elutia (ELUT). These companies are all part of the "biological products, except diagnostic" industry.
Atara Biotherapeutics (NASDAQ:ATRA) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, community ranking, valuation, earnings and risk.
In the previous week, Atara Biotherapeutics and Atara Biotherapeutics both had 1 articles in the media. Atara Biotherapeutics' average media sentiment score of 0.59 beat Athira Pharma's score of 0.27 indicating that Atara Biotherapeutics is being referred to more favorably in the media.
Atara Biotherapeutics received 412 more outperform votes than Athira Pharma when rated by MarketBeat users. Likewise, 67.67% of users gave Atara Biotherapeutics an outperform vote while only 56.67% of users gave Athira Pharma an outperform vote.
Atara Biotherapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 2.77, meaning that its stock price is 177% more volatile than the S&P 500.
Athira Pharma has lower revenue, but higher earnings than Atara Biotherapeutics. Athira Pharma is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Atara Biotherapeutics presently has a consensus price target of $28.00, indicating a potential upside of 3,817.73%. Athira Pharma has a consensus price target of $12.00, indicating a potential upside of 497.01%. Given Atara Biotherapeutics' higher probable upside, research analysts plainly believe Atara Biotherapeutics is more favorable than Athira Pharma.
Athira Pharma has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -3,220.88%. Athira Pharma's return on equity of -69.11% beat Atara Biotherapeutics' return on equity.
70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 4.5% of Atara Biotherapeutics shares are owned by insiders. Comparatively, 17.0% of Athira Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Atara Biotherapeutics and Athira Pharma tied by winning 8 of the 16 factors compared between the two stocks.
Get Atara Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atara Biotherapeutics Competitors List
Related Companies and Tools
